{"id":"NCT01084265","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism","officialTitle":"Clinical Trial on Application of Injectable Recombinant Human Luteinizing Hormone (Luveris®) in the Treatment of Chinese Female Patients With Hypogonadotropic Hypogonadism: A Multi-center, Open, Prospective Drug Clinical Trial for Registration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-02","primaryCompletion":"2005-12","completion":"2005-12","firstPosted":"2010-03-10","resultsPosted":"2012-05-22","lastUpdate":"2013-12-27"},"enrollment":31,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism"],"interventions":[{"type":"DRUG","name":"Recombinant human luteinizing hormone (r-hLH)","otherNames":["Luveris (r-hLH)"]},{"type":"DRUG","name":"Recombinant human follicle-stimulating hormone (r-hFSH)","otherNames":["Gonal-F (r-hFSH)"]},{"type":"DRUG","name":"Human chorionic gonadotropin (hCG)","otherNames":[]}],"arms":[],"summary":"This was a prospective, open, non-comparative study to evaluate the safety and efficacy of recombinant human luteinizing hormone (rhLH, Luveris) administered subcutaneously (s.c.) in follicular development during ovulation induction in 31 Chinese female subjects with hypogonadotropic hypogonadism.","primaryOutcome":{"measure":"Number of Participants Who Met Both Index 1 and Index 2","timeFrame":"Day 14","effectByArm":[{"arm":"Recombinant Human Luteinizing Hormone (Luveris)","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":17,"exclusionCount":11},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":[]}}